Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)
Hisashi Hidaka(Kitasato University), Yasuaki Arai(Tokyo National Hospital), Masafumi Ikeda(National Cancer Center Hospital East), Hitoshi Arioka(Yokohama Rosai Hospital), Masatoshi Kudo(Kindai University), Shinichi Kora(Fukuoka University), Yoshitaka Inaba(Aichi Cancer Center), Takeshi Aramaki(Shizuoka Cancer Center), Junji Furuse(Kanagawa Prefectural Hospital Organization), Namiki Izumi(Musashino Red Cross Hospital), Shuichi Kaneko(Kanazawa University), Hiroya Saito(Asahikawa Kosei Hospital), Takuji Okusaka(National Cancer Centre Japan), Tatsuya Yamashita(Tokyo Metropolitan Police Hospital), Satoshi Morita(Kyoto University), Osamu Yokosuka(Chiba University), Kazuho Imanaka(Osaka International Cancer Institute), Susumu Kanazawa(Okayama University), Osamu Matsui(Kanazawa University)
Cited by 23
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k